Skip to Content
Top

BY Ron Gilmore

Immatics Biotechnologies GmbH (Immatics) and MD Anderson have announced the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.

Immatics believes that ACT approaches to be developed by the new company can change the treatment of cancer by delivering significant, long-lasting clinical benefits. The new company will strive...

BY Ron Gilmore

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information...

BY Ron Gilmore

An MD Anderson study has found that a protein called CSN6 is linked to poor survival among patients with colorectal cancer.

The study...

BY Ron Gilmore

Merck and MD Anderson have announced a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA®å (pembrolizumab), in combination with other treatments such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.

Under the terms of the agreement, collaborative studies will be conducted in the following tumor types over the three-year period of the collaboration: gastroesophageal adenocarcinoma...

BY Laura Sussman

In a first-of-its-kind study, researchers at MD Anderson Cancer Center have demonstrated a benefit in overall survival among epithelial ovarian...

BY Clayton Boldt

MD Anderson has appointed former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D. as the inaugural executive director of the...

BY Ron Gilmore

Scientists know that activation of growth factor receptors such as epidermal growth factor receptors (EGFR) promote tumor progression in many...

BY Scott Merville

For his groundbreaking work in immunotherapy, Jim Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, will receive the nation...